ArticleScience (New York, N.Y.)2020
DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04944095 (Serology Testing), which is not on this map. Cited by 717 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
717citing papers in PubMed, 7 pooled it
26.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Serology Testing (Antibody Levels) With Time Following SARS-CoV-2 (Covid-19) Vaccinations in Residents of Nursing, Extended Care, and Over-55 Communities
Who cites it
717 citing papers in PubMed, 7 syntheses or guidelines pooled it, 1,123 citations in OpenAlex.
- Predicting the presence of infectious virus from PCR data: A meta-analysis of SARS-CoV-2 in non-human primates.PLoS pathogens · 2024Pooled it
- Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis.Lancet (London, England) · 2023Pooled it
- Antibody titers of individuals vaccinated for COVID-19: A systematic review.Journal of biosciences · 2023Pooled it
- Immunogenicity Characterization of COVID-19 Vaccines: A Systematic Review and Meta-analysis.Revista da Sociedade Brasileira de Medicina Tropical · 2023Pooled it
- Coronavirus (SARS-CoV-2): a systematic review for potential vaccines.Human vaccines & immunotherapeutics · 2022Pooled it
- Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach.EBioMedicine · 2022Pooled it
- The prevalence of adaptive immunity to COVID-19 and reinfection after recovery - a comprehensive systematic review and meta-analysis.Pathogens and global health · 2022Pooled it
- Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.Nature microbiology · 2022Trial
- Development and multi-center clinical trials of an up-converting phosphor technology-based point-of-care (UPT-POCT) assay for rapid COVID-19 diagnosis and prediction of protective effects.BMC microbiology · 2022Trial
- Exposure route, not dose, is the primary driver of infection patterns for a respiratory virus.Science advances · 2026Article
- Observational
- A rhesus macaque model of α-dystroglycanopathy caused by a POMT1 splice altering variant.Animal models and experimental medicine · 2026Article
- Development of a recombinant single-cycle influenza viral vector as an intranasal vaccine against SARS-CoV-2.Scientific reports · 2026Article
- The Association of Primate Veterinarians and the European Primate Veterinarians Position Statement on the Value of Nonhuman Primates in Research.Journal of the American Association for Laboratory Animal Science : JAALAS · 2026Article
- Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine.NPJ vaccines · 2026Article
- Vaccine-derived T-cell responses are insufficient to generate protective immunity to SARS-CoV-2.Scientific reports · 2026Article
- Evaluating southern pigtail macaques as an immunological model for human antibody responses.Scientific reports · 2026Article
- Exposure route drives SARS-CoV-2 infection patterns in non-human primates.bioRxiv : the preprint server for biology · 2026Article
- A phase 1, single-center, randomized, dose finding study to evaluate the safety, tolerability, and immunogenicity of a prophylactic COVID-19 pDNA vaccine after single ascending doses in healthy adults.Frontiers in medicine · 2026Article
- Trends of laboratory nonhuman primate licensing in China between 2020 and 2024: A national database analysis.PloS one · 2026Article
657 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
54 authors at 8 institutions in 2 countries.
Jingyou Yu *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-0775-6623
Lisa H Tostanoski *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-9255-5684
Lauren Peter *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-2105-7503
Noe B Mercado *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-7769-7326
Katherine McMahan *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-3933-0539
Shant H Mahrokhian *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0003-4094-8739
Joseph P Nkolola *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-0678-9765
Jinyan Liu *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0003-0504-2181
Zhenfeng Li *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Abishek Chandrashekar *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-7821-5552
David R MartinezDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Carolin LoosRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0003-3680-0627
Caroline AtyeoRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-7489-0232
Stephanie FischingerRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0003-2307-3379
John S BurkeRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0003-1282-8211
Matthew D SleinRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0001-8288-787X
Yuezhou ChenBrigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Adam ZuianiBrigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-2625-6595
Felipe J N LelisBrigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-3708-3810
Meghan TraversBrigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Shaghayegh HabibiBrigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-5209-9220
Laurent PessaintBioqual, Rockville, MD 20852, USA.ORCID 0000-0002-2126-3008
Alex Van RyBioqual, Rockville, MD 20852, USA.ORCID 0000-0002-1240-9044
Kelvin BladeBioqual, Rockville, MD 20852, USA.ORCID 0000-0003-3387-6693
Renita BrownBioqual, Rockville, MD 20852, USA.
Anthony CookBioqual, Rockville, MD 20852, USA.
Brad FinneyfrockBioqual, Rockville, MD 20852, USA.ORCID 0000-0002-1564-5798
Alan DodsonBioqual, Rockville, MD 20852, USA.ORCID 0000-0003-2733-2753
Elyse TeowBioqual, Rockville, MD 20852, USA.
Jason VelascoBioqual, Rockville, MD 20852, USA.
Roland ZahnJanssen Vaccines & Prevention BV, Leiden, Netherlands.ORCID 0000-0003-2822-6231
Frank WegmannJanssen Vaccines & Prevention BV, Leiden, Netherlands.ORCID 0000-0002-9821-1492
Esther A BondzieCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-9409-5052
Gabriel DagottoCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-9872-6074
Makda S GebreCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-8520-2178
Xuan HeCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Catherine Jacob-DolanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-6641-0342
Marinela KirilovaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Nicole KordanaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0003-4082-6029
Zijin LinCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Lori F MaxfieldCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-7595-6205
Felix NampanyaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Ramya NityanandamCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-3288-8505
John D VenturaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-4373-3242
Huahua WanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-6958-9464
Yongfei CaiChildren's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-3628-3802
Bing ChenChildren's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-8625-1657
Aaron G SchmidtRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0003-3627-2553
Duane R WesemannBrigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-6690-944X
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0001-6827-8701
Galit AlterRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-7680-9215
Hanne AndersenBioqual, Rockville, MD 20852, USA.ORCID 0000-0003-1103-9608
Mark G LewisBioqual, Rockville, MD 20852, USA.ORCID 0000-0001-7852-0135
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. dbarouch@bidmc.harvard.edu.ORCID 0000-0001-5127-4659
Beth Israel Deaconess Medical Center · USBioqual · USBrigham and Women's Hospital · USRagon Institute of MGH, MIT and Harvard · USBoston Children's Hospital · USConcord Consortium · USJanssen (Netherlands) · NLUniversity of North Carolina at Chapel Hill · US
Funding
Consortia for Innovative AIDS Research in Nonhuman PrimatesUM1AI124377 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., PICKER, LOUIS J. · 2016 to 2021
$53.0MUnlocking Zika Virus Immune Control and Pathogenesis with the Collaborative CrossU19AI100625 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, HEISE, MARK T · 2012 to 2021
$36.6MCombined Immunologic Approaches to Cure HIV-1UM1AI126603 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., MELLORS, JOHN W · 2016 to 2020
$23.6MProject 2U19AI128751 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ALTER, GALIT · 2018 to 2022
$14.0MMultidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8MMechanisms of MERS-CoV Entry, Cross-species Transmission and PathogenesisR01AI110700 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, LI, FANG · 2015 to 2024
$7.4MBroad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoVR01AI132178 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, SHEAHAN, TIMOTHY PATRICK · 2017 to 2021
$7.0MDeterminants of Coronavirus Fidelity in Replication and PathogenesisR01AI108197 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BARIC, RALPH S, DENISON, MARK R · 2013 to 2022
$6.5MRespiratory Virus Vaccine and Adjuvant Exploration - Equipment SupplementU01AI149644 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S · 2019 to 2023
$6.1MINFECTIOUS DISEASE PATHOGENESIS TRAININGT32AI007151 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, JONATHAN J · 1985 to 2024
$5.5MImpact of the Intestinal Microbiome on HIV/SIV VaccinesR01OD024917 · OD · WASHINGTON UNIVERSITY · PI BALDRIDGE, MEGAN T, BAROUCH, DAN H. · 2017 to 2021
$4.3MEpitope focusing to the receptor binding motif for a universal coronavirus vaccineR01AI146779 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI SCHMIDT, AARON GREGORY · 2019 to 2023
$4.2MNIAID NIH HHS R01 AI108197NIAID NIH HHS R01 AI110700NIAID NIH HHS R01 AI121394NIAID NIH HHS R01 AI129797NIAID NIH HHS R01 AI132178NIAID NIH HHS R01 AI139538NIAID NIH HHS R01 AI146779NIAID NIH HHS R01 AI147884NIAID NIH HHS T32 AI007151NIAID NIH HHS T32 AI007387NIAID NIH HHS U01 AI149644NIAID NIH HHS U19 AI100625NIAID NIH HHS U19 AI128751NIAID NIH HHS UM1 AI124377NIAID NIH HHS UM1 AI126603NIH HHS R01 OD024917
Abstract
The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made the development of a vaccine a top biomedical priority. In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers at levels comparable to those found in convalescent humans and macaques infected with SARS-CoV-2. After vaccination, all animals were challenged with SARS-CoV-2, and the vaccine encoding the full-length S protein resulted in >3.1 and >3.7 log
Indexed as
Adjuvants, ImmunologicAnimalsAntibodies, NeutralizingAntibodies, ViralBetacoronavirusBronchoalveolar Lavage FluidCoronavirus InfectionsCOVID-19COVID-19 VaccinesDisease Models, AnimalFemaleHumansImmunity, CellularImmunity, HumoralImmunization, SecondaryImmunogenicity, VaccineAdjuvants, ImmunologicAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesMutant ProteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, DNAViral Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT04944095ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.